Revolution Medicines Stock Surges Following Positive Pancreatic Cancer Drug Trial Data

Revolution Medicines announced that its highly anticipated drug for pancreatic cancer, daraxonrasib, has succeeded in a Phase 3 clinical trial, leading to a surge in the company's stock. This represents a potential breakthrough in treating the aggressive disease.